Bill Text: IL HB2488 | 2019-2020 | 101st General Assembly | Enrolled


Bill Title: Amends the Illinois Controlled Substances Act. Provides that the Bureau of Pharmacy and Clinical Support Systems shall establish a form to allow electronic health record systems to certify the identity of a third party that will provide access to the Prescription Information Library for the electronic health record system using all or part of a computer program or system that is a federally certified Health IT Module for the electronic health record system. Provides that before the Health IT Module is permitted to connect to the Prescription Information Library, it must enter into a business associate agreement with the electronic health record system that requires the Health IT Module to agree to adhere to all requirements imposed on the electronic health record system by the laws of this State. Defines "electronic health record system".

Spectrum: Partisan Bill (Democrat 5-0)

Status: (Enrolled - Dead) 2021-01-13 - Passed Both Houses [HB2488 Detail]

Download: Illinois-2019-HB2488-Enrolled.html



HB2488 EnrolledLRB101 07727 CPF 52776 b
1 AN ACT concerning regulation.
2 Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
4 Section 5. The Illinois Controlled Substances Act is
5amended by changing Section 102 and by adding Section 220 as
6follows:
7 (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102)
8 Sec. 102. Definitions. As used in this Act, unless the
9context otherwise requires:
10 (a) "Addict" means any person who habitually uses any drug,
11chemical, substance or dangerous drug other than alcohol so as
12to endanger the public morals, health, safety or welfare or who
13is so far addicted to the use of a dangerous drug or controlled
14substance other than alcohol as to have lost the power of self
15control with reference to his or her addiction.
16 (b) "Administer" means the direct application of a
17controlled substance, whether by injection, inhalation,
18ingestion, or any other means, to the body of a patient,
19research subject, or animal (as defined by the Humane
20Euthanasia in Animal Shelters Act) by:
21 (1) a practitioner (or, in his or her presence, by his
22 or her authorized agent),
23 (2) the patient or research subject pursuant to an

HB2488 Enrolled- 2 -LRB101 07727 CPF 52776 b
1 order, or
2 (3) a euthanasia technician as defined by the Humane
3 Euthanasia in Animal Shelters Act.
4 (c) "Agent" means an authorized person who acts on behalf
5of or at the direction of a manufacturer, distributor,
6dispenser, prescriber, or practitioner. It does not include a
7common or contract carrier, public warehouseman or employee of
8the carrier or warehouseman.
9 (c-1) "Anabolic Steroids" means any drug or hormonal
10substance, chemically and pharmacologically related to
11testosterone (other than estrogens, progestins,
12corticosteroids, and dehydroepiandrosterone), and includes:
13 (i) 3[beta],17-dihydroxy-5a-androstane,
14 (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane,
15 (iii) 5[alpha]-androstan-3,17-dione,
16 (iv) 1-androstenediol (3[beta],
17 17[beta]-dihydroxy-5[alpha]-androst-1-ene),
18 (v) 1-androstenediol (3[alpha],
19 17[beta]-dihydroxy-5[alpha]-androst-1-ene),
20 (vi) 4-androstenediol
21 (3[beta],17[beta]-dihydroxy-androst-4-ene),
22 (vii) 5-androstenediol
23 (3[beta],17[beta]-dihydroxy-androst-5-ene),
24 (viii) 1-androstenedione
25 ([5alpha]-androst-1-en-3,17-dione),
26 (ix) 4-androstenedione

HB2488 Enrolled- 3 -LRB101 07727 CPF 52776 b
1 (androst-4-en-3,17-dione),
2 (x) 5-androstenedione
3 (androst-5-en-3,17-dione),
4 (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]-
5 hydroxyandrost-4-en-3-one),
6 (xii) boldenone (17[beta]-hydroxyandrost-
7 1,4,-diene-3-one),
8 (xiii) boldione (androsta-1,4-
9 diene-3,17-dione),
10 (xiv) calusterone (7[beta],17[alpha]-dimethyl-17
11 [beta]-hydroxyandrost-4-en-3-one),
12 (xv) clostebol (4-chloro-17[beta]-
13 hydroxyandrost-4-en-3-one),
14 (xvi) dehydrochloromethyltestosterone (4-chloro-
15 17[beta]-hydroxy-17[alpha]-methyl-
16 androst-1,4-dien-3-one),
17 (xvii) desoxymethyltestosterone
18 (17[alpha]-methyl-5[alpha]
19 -androst-2-en-17[beta]-ol)(a.k.a., madol),
20 (xviii) [delta]1-dihydrotestosterone (a.k.a.
21 '1-testosterone') (17[beta]-hydroxy-
22 5[alpha]-androst-1-en-3-one),
23 (xix) 4-dihydrotestosterone (17[beta]-hydroxy-
24 androstan-3-one),
25 (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl-
26 5[alpha]-androstan-3-one),

HB2488 Enrolled- 4 -LRB101 07727 CPF 52776 b
1 (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-
2 hydroxyestr-4-ene),
3 (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-
4 1[beta],17[beta]-dihydroxyandrost-4-en-3-one),
5 (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],
6 17[beta]-dihydroxyandrost-1,4-dien-3-one),
7 (xxiv) furazabol (17[alpha]-methyl-17[beta]-
8 hydroxyandrostano[2,3-c]-furazan),
9 (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one,
10 (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy-
11 androst-4-en-3-one),
12 (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]-
13 dihydroxy-estr-4-en-3-one),
14 (xxviii) mestanolone (17[alpha]-methyl-17[beta]-
15 hydroxy-5-androstan-3-one),
16 (xxix) mesterolone (1amethyl-17[beta]-hydroxy-
17 [5a]-androstan-3-one),
18 (xxx) methandienone (17[alpha]-methyl-17[beta]-
19 hydroxyandrost-1,4-dien-3-one),
20 (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]-
21 dihydroxyandrost-5-ene),
22 (xxxii) methenolone (1-methyl-17[beta]-hydroxy-
23 5[alpha]-androst-1-en-3-one),
24 (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]-
25 dihydroxy-5a-androstane,
26 (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy

HB2488 Enrolled- 5 -LRB101 07727 CPF 52776 b
1 -5a-androstane,
2 (xxxv) 17[alpha]-methyl-3[beta],17[beta]-
3 dihydroxyandrost-4-ene),
4 (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-
5 methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one),
6 (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-
7 hydroxyestra-4,9(10)-dien-3-one),
8 (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-
9 hydroxyestra-4,9-11-trien-3-one),
10 (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-
11 hydroxyandrost-4-en-3-one),
12 (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]-
13 hydroxyestr-4-en-3-one),
14 (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
15 (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-
16 androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl-
17 1-testosterone'),
18 (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one),
19 (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]-
20 dihydroxyestr-4-ene),
21 (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]-
22 dihydroxyestr-4-ene),
23 (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]-
24 dihydroxyestr-5-ene),
25 (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]-
26 dihydroxyestr-5-ene),

HB2488 Enrolled- 6 -LRB101 07727 CPF 52776 b
1 (xlvii) 19-nor-4,9(10)-androstadienedione
2 (estra-4,9(10)-diene-3,17-dione),
3 (xlviii) 19-nor-4-androstenedione (estr-4-
4 en-3,17-dione),
5 (xlix) 19-nor-5-androstenedione (estr-5-
6 en-3,17-dione),
7 (l) norbolethone (13[beta], 17a-diethyl-17[beta]-
8 hydroxygon-4-en-3-one),
9 (li) norclostebol (4-chloro-17[beta]-
10 hydroxyestr-4-en-3-one),
11 (lii) norethandrolone (17[alpha]-ethyl-17[beta]-
12 hydroxyestr-4-en-3-one),
13 (liii) normethandrolone (17[alpha]-methyl-17[beta]-
14 hydroxyestr-4-en-3-one),
15 (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-
16 2-oxa-5[alpha]-androstan-3-one),
17 (lv) oxymesterone (17[alpha]-methyl-4,17[beta]-
18 dihydroxyandrost-4-en-3-one),
19 (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-
20 17[beta]-hydroxy-(5[alpha]-androstan-3-one),
21 (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-
22 (5[alpha]-androst-2-eno[3,2-c]-pyrazole),
23 (lviii) stenbolone (17[beta]-hydroxy-2-methyl-
24 (5[alpha]-androst-1-en-3-one),
25 (lix) testolactone (13-hydroxy-3-oxo-13,17-
26 secoandrosta-1,4-dien-17-oic

HB2488 Enrolled- 7 -LRB101 07727 CPF 52776 b
1 acid lactone),
2 (lx) testosterone (17[beta]-hydroxyandrost-
3 4-en-3-one),
4 (lxi) tetrahydrogestrinone (13[beta], 17[alpha]-
5 diethyl-17[beta]-hydroxygon-
6 4,9,11-trien-3-one),
7 (lxii) trenbolone (17[beta]-hydroxyestr-4,9,
8 11-trien-3-one).
9 Any person who is otherwise lawfully in possession of an
10anabolic steroid, or who otherwise lawfully manufactures,
11distributes, dispenses, delivers, or possesses with intent to
12deliver an anabolic steroid, which anabolic steroid is
13expressly intended for and lawfully allowed to be administered
14through implants to livestock or other nonhuman species, and
15which is approved by the Secretary of Health and Human Services
16for such administration, and which the person intends to
17administer or have administered through such implants, shall
18not be considered to be in unauthorized possession or to
19unlawfully manufacture, distribute, dispense, deliver, or
20possess with intent to deliver such anabolic steroid for
21purposes of this Act.
22 (d) "Administration" means the Drug Enforcement
23Administration, United States Department of Justice, or its
24successor agency.
25 (d-5) "Clinical Director, Prescription Monitoring Program"
26means a Department of Human Services administrative employee

HB2488 Enrolled- 8 -LRB101 07727 CPF 52776 b
1licensed to either prescribe or dispense controlled substances
2who shall run the clinical aspects of the Department of Human
3Services Prescription Monitoring Program and its Prescription
4Information Library.
5 (d-10) "Compounding" means the preparation and mixing of
6components, excluding flavorings, (1) as the result of a
7prescriber's prescription drug order or initiative based on the
8prescriber-patient-pharmacist relationship in the course of
9professional practice or (2) for the purpose of, or incident
10to, research, teaching, or chemical analysis and not for sale
11or dispensing. "Compounding" includes the preparation of drugs
12or devices in anticipation of receiving prescription drug
13orders based on routine, regularly observed dispensing
14patterns. Commercially available products may be compounded
15for dispensing to individual patients only if both of the
16following conditions are met: (i) the commercial product is not
17reasonably available from normal distribution channels in a
18timely manner to meet the patient's needs and (ii) the
19prescribing practitioner has requested that the drug be
20compounded.
21 (e) "Control" means to add a drug or other substance, or
22immediate precursor, to a Schedule whether by transfer from
23another Schedule or otherwise.
24 (f) "Controlled Substance" means (i) a drug, substance,
25immediate precursor, or synthetic drug in the Schedules of
26Article II of this Act or (ii) a drug or other substance, or

HB2488 Enrolled- 9 -LRB101 07727 CPF 52776 b
1immediate precursor, designated as a controlled substance by
2the Department through administrative rule. The term does not
3include distilled spirits, wine, malt beverages, or tobacco, as
4those terms are defined or used in the Liquor Control Act of
51934 and the Tobacco Products Tax Act of 1995.
6 (f-5) "Controlled substance analog" means a substance:
7 (1) the chemical structure of which is substantially
8 similar to the chemical structure of a controlled substance
9 in Schedule I or II;
10 (2) which has a stimulant, depressant, or
11 hallucinogenic effect on the central nervous system that is
12 substantially similar to or greater than the stimulant,
13 depressant, or hallucinogenic effect on the central
14 nervous system of a controlled substance in Schedule I or
15 II; or
16 (3) with respect to a particular person, which such
17 person represents or intends to have a stimulant,
18 depressant, or hallucinogenic effect on the central
19 nervous system that is substantially similar to or greater
20 than the stimulant, depressant, or hallucinogenic effect
21 on the central nervous system of a controlled substance in
22 Schedule I or II.
23 (g) "Counterfeit substance" means a controlled substance,
24which, or the container or labeling of which, without
25authorization bears the trademark, trade name, or other
26identifying mark, imprint, number or device, or any likeness

HB2488 Enrolled- 10 -LRB101 07727 CPF 52776 b
1thereof, of a manufacturer, distributor, or dispenser other
2than the person who in fact manufactured, distributed, or
3dispensed the substance.
4 (h) "Deliver" or "delivery" means the actual, constructive
5or attempted transfer of possession of a controlled substance,
6with or without consideration, whether or not there is an
7agency relationship.
8 (i) "Department" means the Illinois Department of Human
9Services (as successor to the Department of Alcoholism and
10Substance Abuse) or its successor agency.
11 (j) (Blank).
12 (k) "Department of Corrections" means the Department of
13Corrections of the State of Illinois or its successor agency.
14 (l) "Department of Financial and Professional Regulation"
15means the Department of Financial and Professional Regulation
16of the State of Illinois or its successor agency.
17 (m) "Depressant" means any drug that (i) causes an overall
18depression of central nervous system functions, (ii) causes
19impaired consciousness and awareness, and (iii) can be
20habit-forming or lead to a substance abuse problem, including
21but not limited to alcohol, cannabis and its active principles
22and their analogs, benzodiazepines and their analogs,
23barbiturates and their analogs, opioids (natural and
24synthetic) and their analogs, and chloral hydrate and similar
25sedative hypnotics.
26 (n) (Blank).

HB2488 Enrolled- 11 -LRB101 07727 CPF 52776 b
1 (o) "Director" means the Director of the Illinois State
2Police or his or her designated agents.
3 (p) "Dispense" means to deliver a controlled substance to
4an ultimate user or research subject by or pursuant to the
5lawful order of a prescriber, including the prescribing,
6administering, packaging, labeling, or compounding necessary
7to prepare the substance for that delivery.
8 (q) "Dispenser" means a practitioner who dispenses.
9 (r) "Distribute" means to deliver, other than by
10administering or dispensing, a controlled substance.
11 (s) "Distributor" means a person who distributes.
12 (t) "Drug" means (1) substances recognized as drugs in the
13official United States Pharmacopoeia, Official Homeopathic
14Pharmacopoeia of the United States, or official National
15Formulary, or any supplement to any of them; (2) substances
16intended for use in diagnosis, cure, mitigation, treatment, or
17prevention of disease in man or animals; (3) substances (other
18than food) intended to affect the structure of any function of
19the body of man or animals and (4) substances intended for use
20as a component of any article specified in clause (1), (2), or
21(3) of this subsection. It does not include devices or their
22components, parts, or accessories.
23 (t-3) "Electronic health record" or "EHR" means an
24electronic record of health-related information on an
25individual that is created, gathered, managed, and consulted by
26authorized health care clinicians and staff.

HB2488 Enrolled- 12 -LRB101 07727 CPF 52776 b
1 (t-3.5) "Electronic health record system" or "EHR system"
2means any computer-based system or combination of federally
3certified Health IT Modules (defined at 42 CFR 170.102 or its
4successor) used as a repository for electronic health records
5and accessed or updated by a prescriber or authorized surrogate
6in the ordinary course of his or her medical practice. For
7purposes of connecting to the Prescription Information Library
8maintained by the Bureau of Pharmacy and Clinical Support
9Systems or its successor, an EHR system may connect to the
10Prescription Information Library directly or through all or
11part of a computer program or system that is a federally
12certified Health IT Module maintained by a third party and used
13by the EHR system to secure access to the database.
14 (t-4) "Emergency medical services personnel" has the
15meaning ascribed to it in the Emergency Medical Services (EMS)
16Systems Act.
17 (t-5) "Euthanasia agency" means an entity certified by the
18Department of Financial and Professional Regulation for the
19purpose of animal euthanasia that holds an animal control
20facility license or animal shelter license under the Animal
21Welfare Act. A euthanasia agency is authorized to purchase,
22store, possess, and utilize Schedule II nonnarcotic and
23Schedule III nonnarcotic drugs for the sole purpose of animal
24euthanasia.
25 (t-10) "Euthanasia drugs" means Schedule II or Schedule III
26substances (nonnarcotic controlled substances) that are used

HB2488 Enrolled- 13 -LRB101 07727 CPF 52776 b
1by a euthanasia agency for the purpose of animal euthanasia.
2 (u) "Good faith" means the prescribing or dispensing of a
3controlled substance by a practitioner in the regular course of
4professional treatment to or for any person who is under his or
5her treatment for a pathology or condition other than that
6individual's physical or psychological dependence upon or
7addiction to a controlled substance, except as provided herein:
8and application of the term to a pharmacist shall mean the
9dispensing of a controlled substance pursuant to the
10prescriber's order which in the professional judgment of the
11pharmacist is lawful. The pharmacist shall be guided by
12accepted professional standards including, but not limited to
13the following, in making the judgment:
14 (1) lack of consistency of prescriber-patient
15 relationship,
16 (2) frequency of prescriptions for same drug by one
17 prescriber for large numbers of patients,
18 (3) quantities beyond those normally prescribed,
19 (4) unusual dosages (recognizing that there may be
20 clinical circumstances where more or less than the usual
21 dose may be used legitimately),
22 (5) unusual geographic distances between patient,
23 pharmacist and prescriber,
24 (6) consistent prescribing of habit-forming drugs.
25 (u-0.5) "Hallucinogen" means a drug that causes markedly
26altered sensory perception leading to hallucinations of any

HB2488 Enrolled- 14 -LRB101 07727 CPF 52776 b
1type.
2 (u-1) "Home infusion services" means services provided by a
3pharmacy in compounding solutions for direct administration to
4a patient in a private residence, long-term care facility, or
5hospice setting by means of parenteral, intravenous,
6intramuscular, subcutaneous, or intraspinal infusion.
7 (u-5) "Illinois State Police" means the State Police of the
8State of Illinois, or its successor agency.
9 (v) "Immediate precursor" means a substance:
10 (1) which the Department has found to be and by rule
11 designated as being a principal compound used, or produced
12 primarily for use, in the manufacture of a controlled
13 substance;
14 (2) which is an immediate chemical intermediary used or
15 likely to be used in the manufacture of such controlled
16 substance; and
17 (3) the control of which is necessary to prevent,
18 curtail or limit the manufacture of such controlled
19 substance.
20 (w) "Instructional activities" means the acts of teaching,
21educating or instructing by practitioners using controlled
22substances within educational facilities approved by the State
23Board of Education or its successor agency.
24 (x) "Local authorities" means a duly organized State,
25County or Municipal peace unit or police force.
26 (y) "Look-alike substance" means a substance, other than a

HB2488 Enrolled- 15 -LRB101 07727 CPF 52776 b
1controlled substance which (1) by overall dosage unit
2appearance, including shape, color, size, markings or lack
3thereof, taste, consistency, or any other identifying physical
4characteristic of the substance, would lead a reasonable person
5to believe that the substance is a controlled substance, or (2)
6is expressly or impliedly represented to be a controlled
7substance or is distributed under circumstances which would
8lead a reasonable person to believe that the substance is a
9controlled substance. For the purpose of determining whether
10the representations made or the circumstances of the
11distribution would lead a reasonable person to believe the
12substance to be a controlled substance under this clause (2) of
13subsection (y), the court or other authority may consider the
14following factors in addition to any other factor that may be
15relevant:
16 (a) statements made by the owner or person in control
17 of the substance concerning its nature, use or effect;
18 (b) statements made to the buyer or recipient that the
19 substance may be resold for profit;
20 (c) whether the substance is packaged in a manner
21 normally used for the illegal distribution of controlled
22 substances;
23 (d) whether the distribution or attempted distribution
24 included an exchange of or demand for money or other
25 property as consideration, and whether the amount of the
26 consideration was substantially greater than the

HB2488 Enrolled- 16 -LRB101 07727 CPF 52776 b
1 reasonable retail market value of the substance.
2 Clause (1) of this subsection (y) shall not apply to a
3noncontrolled substance in its finished dosage form that was
4initially introduced into commerce prior to the initial
5introduction into commerce of a controlled substance in its
6finished dosage form which it may substantially resemble.
7 Nothing in this subsection (y) prohibits the dispensing or
8distributing of noncontrolled substances by persons authorized
9to dispense and distribute controlled substances under this
10Act, provided that such action would be deemed to be carried
11out in good faith under subsection (u) if the substances
12involved were controlled substances.
13 Nothing in this subsection (y) or in this Act prohibits the
14manufacture, preparation, propagation, compounding,
15processing, packaging, advertising or distribution of a drug or
16drugs by any person registered pursuant to Section 510 of the
17Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
18 (y-1) "Mail-order pharmacy" means a pharmacy that is
19located in a state of the United States that delivers,
20dispenses or distributes, through the United States Postal
21Service or other common carrier, to Illinois residents, any
22substance which requires a prescription.
23 (z) "Manufacture" means the production, preparation,
24propagation, compounding, conversion or processing of a
25controlled substance other than methamphetamine, either
26directly or indirectly, by extraction from substances of

HB2488 Enrolled- 17 -LRB101 07727 CPF 52776 b
1natural origin, or independently by means of chemical
2synthesis, or by a combination of extraction and chemical
3synthesis, and includes any packaging or repackaging of the
4substance or labeling of its container, except that this term
5does not include:
6 (1) by an ultimate user, the preparation or compounding
7 of a controlled substance for his or her own use; or
8 (2) by a practitioner, or his or her authorized agent
9 under his or her supervision, the preparation,
10 compounding, packaging, or labeling of a controlled
11 substance:
12 (a) as an incident to his or her administering or
13 dispensing of a controlled substance in the course of
14 his or her professional practice; or
15 (b) as an incident to lawful research, teaching or
16 chemical analysis and not for sale.
17 (z-1) (Blank).
18 (z-5) "Medication shopping" means the conduct prohibited
19under subsection (a) of Section 314.5 of this Act.
20 (z-10) "Mid-level practitioner" means (i) a physician
21assistant who has been delegated authority to prescribe through
22a written delegation of authority by a physician licensed to
23practice medicine in all of its branches, in accordance with
24Section 7.5 of the Physician Assistant Practice Act of 1987,
25(ii) an advanced practice registered nurse who has been
26delegated authority to prescribe through a written delegation

HB2488 Enrolled- 18 -LRB101 07727 CPF 52776 b
1of authority by a physician licensed to practice medicine in
2all of its branches or by a podiatric physician, in accordance
3with Section 65-40 of the Nurse Practice Act, (iii) an advanced
4practice registered nurse certified as a nurse practitioner,
5nurse midwife, or clinical nurse specialist who has been
6granted authority to prescribe by a hospital affiliate in
7accordance with Section 65-45 of the Nurse Practice Act, (iv)
8an animal euthanasia agency, or (v) a prescribing psychologist.
9 (aa) "Narcotic drug" means any of the following, whether
10produced directly or indirectly by extraction from substances
11of vegetable origin, or independently by means of chemical
12synthesis, or by a combination of extraction and chemical
13synthesis:
14 (1) opium, opiates, derivatives of opium and opiates,
15 including their isomers, esters, ethers, salts, and salts
16 of isomers, esters, and ethers, whenever the existence of
17 such isomers, esters, ethers, and salts is possible within
18 the specific chemical designation; however the term
19 "narcotic drug" does not include the isoquinoline
20 alkaloids of opium;
21 (2) (blank);
22 (3) opium poppy and poppy straw;
23 (4) coca leaves, except coca leaves and extracts of
24 coca leaves from which substantially all of the cocaine and
25 ecgonine, and their isomers, derivatives and salts, have
26 been removed;

HB2488 Enrolled- 19 -LRB101 07727 CPF 52776 b
1 (5) cocaine, its salts, optical and geometric isomers,
2 and salts of isomers;
3 (6) ecgonine, its derivatives, their salts, isomers,
4 and salts of isomers;
5 (7) any compound, mixture, or preparation which
6 contains any quantity of any of the substances referred to
7 in subparagraphs (1) through (6).
8 (bb) "Nurse" means a registered nurse licensed under the
9Nurse Practice Act.
10 (cc) (Blank).
11 (dd) "Opiate" means any substance having an addiction
12forming or addiction sustaining liability similar to morphine
13or being capable of conversion into a drug having addiction
14forming or addiction sustaining liability.
15 (ee) "Opium poppy" means the plant of the species Papaver
16somniferum L., except its seeds.
17 (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
18solution or other liquid form of medication intended for
19administration by mouth, but the term does not include a form
20of medication intended for buccal, sublingual, or transmucosal
21administration.
22 (ff) "Parole and Pardon Board" means the Parole and Pardon
23Board of the State of Illinois or its successor agency.
24 (gg) "Person" means any individual, corporation,
25mail-order pharmacy, government or governmental subdivision or
26agency, business trust, estate, trust, partnership or

HB2488 Enrolled- 20 -LRB101 07727 CPF 52776 b
1association, or any other entity.
2 (hh) "Pharmacist" means any person who holds a license or
3certificate of registration as a registered pharmacist, a local
4registered pharmacist or a registered assistant pharmacist
5under the Pharmacy Practice Act.
6 (ii) "Pharmacy" means any store, ship or other place in
7which pharmacy is authorized to be practiced under the Pharmacy
8Practice Act.
9 (ii-5) "Pharmacy shopping" means the conduct prohibited
10under subsection (b) of Section 314.5 of this Act.
11 (ii-10) "Physician" (except when the context otherwise
12requires) means a person licensed to practice medicine in all
13of its branches.
14 (jj) "Poppy straw" means all parts, except the seeds, of
15the opium poppy, after mowing.
16 (kk) "Practitioner" means a physician licensed to practice
17medicine in all its branches, dentist, optometrist, podiatric
18physician, veterinarian, scientific investigator, pharmacist,
19physician assistant, advanced practice registered nurse,
20licensed practical nurse, registered nurse, emergency medical
21services personnel, hospital, laboratory, or pharmacy, or
22other person licensed, registered, or otherwise lawfully
23permitted by the United States or this State to distribute,
24dispense, conduct research with respect to, administer or use
25in teaching or chemical analysis, a controlled substance in the
26course of professional practice or research.

HB2488 Enrolled- 21 -LRB101 07727 CPF 52776 b
1 (ll) "Pre-printed prescription" means a written
2prescription upon which the designated drug has been indicated
3prior to the time of issuance; the term does not mean a written
4prescription that is individually generated by machine or
5computer in the prescriber's office.
6 (mm) "Prescriber" means a physician licensed to practice
7medicine in all its branches, dentist, optometrist,
8prescribing psychologist licensed under Section 4.2 of the
9Clinical Psychologist Licensing Act with prescriptive
10authority delegated under Section 4.3 of the Clinical
11Psychologist Licensing Act, podiatric physician, or
12veterinarian who issues a prescription, a physician assistant
13who issues a prescription for a controlled substance in
14accordance with Section 303.05, a written delegation, and a
15written collaborative agreement required under Section 7.5 of
16the Physician Assistant Practice Act of 1987, an advanced
17practice registered nurse with prescriptive authority
18delegated under Section 65-40 of the Nurse Practice Act and in
19accordance with Section 303.05, a written delegation, and a
20written collaborative agreement under Section 65-35 of the
21Nurse Practice Act, an advanced practice registered nurse
22certified as a nurse practitioner, nurse midwife, or clinical
23nurse specialist who has been granted authority to prescribe by
24a hospital affiliate in accordance with Section 65-45 of the
25Nurse Practice Act and in accordance with Section 303.05, or an
26advanced practice registered nurse certified as a nurse

HB2488 Enrolled- 22 -LRB101 07727 CPF 52776 b
1practitioner, nurse midwife, or clinical nurse specialist who
2has full practice authority pursuant to Section 65-43 of the
3Nurse Practice Act.
4 (nn) "Prescription" means a written, facsimile, or oral
5order, or an electronic order that complies with applicable
6federal requirements, of a physician licensed to practice
7medicine in all its branches, dentist, podiatric physician or
8veterinarian for any controlled substance, of an optometrist in
9accordance with Section 15.1 of the Illinois Optometric
10Practice Act of 1987, of a prescribing psychologist licensed
11under Section 4.2 of the Clinical Psychologist Licensing Act
12with prescriptive authority delegated under Section 4.3 of the
13Clinical Psychologist Licensing Act, of a physician assistant
14for a controlled substance in accordance with Section 303.05, a
15written delegation, and a written collaborative agreement
16required under Section 7.5 of the Physician Assistant Practice
17Act of 1987, of an advanced practice registered nurse with
18prescriptive authority delegated under Section 65-40 of the
19Nurse Practice Act who issues a prescription for a controlled
20substance in accordance with Section 303.05, a written
21delegation, and a written collaborative agreement under
22Section 65-35 of the Nurse Practice Act, of an advanced
23practice registered nurse certified as a nurse practitioner,
24nurse midwife, or clinical nurse specialist who has been
25granted authority to prescribe by a hospital affiliate in
26accordance with Section 65-45 of the Nurse Practice Act and in

HB2488 Enrolled- 23 -LRB101 07727 CPF 52776 b
1accordance with Section 303.05 when required by law, or of an
2advanced practice registered nurse certified as a nurse
3practitioner, nurse midwife, or clinical nurse specialist who
4has full practice authority pursuant to Section 65-43 of the
5Nurse Practice Act.
6 (nn-5) "Prescription Information Library" (PIL) means an
7electronic library that contains reported controlled substance
8data.
9 (nn-10) "Prescription Monitoring Program" (PMP) means the
10entity that collects, tracks, and stores reported data on
11controlled substances and select drugs pursuant to Section 316.
12 (oo) "Production" or "produce" means manufacture,
13planting, cultivating, growing, or harvesting of a controlled
14substance other than methamphetamine.
15 (pp) "Registrant" means every person who is required to
16register under Section 302 of this Act.
17 (qq) "Registry number" means the number assigned to each
18person authorized to handle controlled substances under the
19laws of the United States and of this State.
20 (qq-5) "Secretary" means, as the context requires, either
21the Secretary of the Department or the Secretary of the
22Department of Financial and Professional Regulation, and the
23Secretary's designated agents.
24 (rr) "State" includes the State of Illinois and any state,
25district, commonwealth, territory, insular possession thereof,
26and any area subject to the legal authority of the United

HB2488 Enrolled- 24 -LRB101 07727 CPF 52776 b
1States of America.
2 (rr-5) "Stimulant" means any drug that (i) causes an
3overall excitation of central nervous system functions, (ii)
4causes impaired consciousness and awareness, and (iii) can be
5habit-forming or lead to a substance abuse problem, including
6but not limited to amphetamines and their analogs,
7methylphenidate and its analogs, cocaine, and phencyclidine
8and its analogs.
9 (rr-10) "Synthetic drug" includes, but is not limited to,
10any synthetic cannabinoids or piperazines or any synthetic
11cathinones as provided for in Schedule I.
12 (ss) "Ultimate user" means a person who lawfully possesses
13a controlled substance for his or her own use or for the use of
14a member of his or her household or for administering to an
15animal owned by him or her or by a member of his or her
16household.
17(Source: P.A. 99-78, eff. 7-20-15; 99-173, eff. 7-29-15;
1899-371, eff. 1-1-16; 99-480, eff. 9-9-15; 99-642, eff. 7-28-16;
19100-280, eff. 1-1-18; 100-453, eff. 8-25-17; 100-513, eff.
201-1-18; 100-789, eff. 1-1-19; 100-863, eff. 8-14-18.)
21 (720 ILCS 570/220 new)
22 Sec. 220. Electronic health record systems. The Bureau of
23Pharmacy and Clinical Support Systems shall establish a form to
24allow EHR systems to certify the identity of a third party that
25will provide access to the Prescription Information Library for

HB2488 Enrolled- 25 -LRB101 07727 CPF 52776 b
1the EHR system using all or part of a computer program or
2system that is a federally certified Health IT Module for the
3EHR system. Before the Health IT Module is permitted to connect
4to the Prescription Information Library, it must enter into a
5business associate agreement with the EHR system that requires
6the Health IT Module to agree to adhere to all requirements
7imposed on the EHR system by the laws of this State, including
8data privacy and security obligations that the Bureau otherwise
9imposes on EHR systems.
feedback